학술논문

Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
Document Type
Article
Source
In: Cell Reports Medicine. (Cell Reports Medicine, 20 September 2022, 3(9))
Subject
Language
English
ISSN
26663791